Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
September 1st is World Chronic Lymphocytic Leukaemia (CLL) Day, the most common leukaemia in adults. Most patients with CLL respond well to treatment1
A recent report from an organisation linked to the WHO states that talc is probably carcinogenic to humans. The use of talc is considered to increase1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
Researchers at the Clínic-IDIBAPS coordinated a study published in Blood Cancer Journal in which a new 3D system was developed from patient samples t1
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
The BBVA Foundation – Hospital Clínic de Barcelona Advanced Research Contracts are aimed at specialists in the Health Sciences, with experience in re1
The goal of the current campaign is to reach 1,000 hours of cancer research. For each book read, 10 minutes of research, and for every six books, one1
